World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
63054
World Ranking
2704
National Ranking
1510

Research.com Recognitions

  • 2017 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John V. Heymach is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine with significant contributions to oncology and pulmonary and respiratory medicine. Their work also spans molecular biology and immunology, reflecting an interdisciplinary approach to cancer research.

The scientist's publication record includes numerous papers in key academic venues. These frequent publication venues feature:

  • Cancer Research
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research

Heymach's main fields of study encompass medicine and biochemistry, genetics, and molecular biology. Their subfields provide further detail, highlighting oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and immunology. These areas align with the primary topics covered in their research:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research

Among recent papers attributed to Heymach are:

  • Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer, 2023, New England Journal of Medicine
  • Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, 2021, Cancer Cell
  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations, 2020, New England Journal of Medicine
  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, 2020, The Lancet Respiratory Medicine

The scientist has collaborated extensively with other researchers. Frequent co-authors include:

  • Don L. Gibbons
  • Jianjun Zhang
  • Xiuning Le
  • Ignacio I. Wistuba
  • Tina Cascone

John V. Heymach's contributions to the field have been recognized by several honors, including being named a Fellow of the American Association for the Advancement of Science (AAAS) in 2017 and membership in the Association of American Physicians.

Best Publications

  • Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

    Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger

  • Comprehensive genomic characterization of squamous cell lung cancers

    Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  • Molecular origins of cancer: Lung cancer

    Roy S. Herbst;John V. Heymach;Scott M. Lippman;Scott M. Lippman

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny

  • Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

    Daniel R. Gomez;Chad Tang;Jianjun Zhang;George R. Blumenschein

  • Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez

  • Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

    Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez

  • The BATTLE Trial: Personalizing Therapy for Lung Cancer

    Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee

  • Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

    Jianjun Zhang;Junya Fujimoto;Jianhua Zhang;David C. Wedge

  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

    Charles M. Rudin;John T. Poirier;Lauren Averett Byers;Caroline Dive

  • PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits

  • Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

    Ferdinandos Skoulidis;John V. Heymach

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

    Triparna Sen;B. Leticia Rodriguez;Limo Chen;Carminia Della Corte

  • Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

    C. Allison Stewart;Elizabeth M. Park;Lixia Diao

  • A pan-cancer proteomic perspective on The Cancer Genome Atlas

    Rehan Akbani;Patrick Kwok Shing Ng;Henrica M.J. Werner;Maria Shahmoradgoli

  • Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

    Nathan T. Ihle;Lauren Averett Byers;Edward S. Kim;Pierre Saintigny

  • Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

    Lauren Averett Byers;Jing Wang;Monique B. Nilsson;Junya Fujimoto

  • Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

    Jeffrey A. Engelman;Toru Mukohara;Kreshnik Zejnullahu;Eugene Lifshits

Frequent Co-Authors

Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Jing Wang
Jing Wang The University of Texas MD Anderson Cancer Center
Don L. Gibbons
Don L. Gibbons The University of Texas MD Anderson Cancer Center
Lixia Diao
Lixia Diao The University of Texas MD Anderson Cancer Center
Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center
Carmen Behrens
Carmen Behrens The University of Texas MD Anderson Cancer Center
John D. Minna
John D. Minna The University of Texas Southwestern Medical Center
Jack A. Roth
Jack A. Roth The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up a range of related paths in the healthcare field—many of which can be accessed through flexible online programs. Students looking for alternatives to traditional medical school or seeking to supplement their education will find a variety of options tailored to different interests and needs.

For those aiming to enter nursing with fewer exam barriers, lpn to rn programs without teas test can be an efficient way to advance your qualifications. Aspiring nurse practitioners can also benefit from asn to np bridge programs, which help registered nurses take the next step toward advanced practice, all while studying online.

If you’re interested in the leadership side of healthcare, a healthcare administration degree online accredited provides business and managerial skills needed to run hospitals, clinics, and other health organizations.

There is also growing demand for nutrition and wellness experts. A bachelor's in nutrition online can prepare you for careers in public health, wellness coaching, or dietetics.

Best Scientists Citing John V. Heymach

Trending Scientists

Recently Published Articles